BR112023021037A2 - Terapia gênica para cardiomiopatia ventricular direita arritmogênica - Google Patents

Terapia gênica para cardiomiopatia ventricular direita arritmogênica

Info

Publication number
BR112023021037A2
BR112023021037A2 BR112023021037A BR112023021037A BR112023021037A2 BR 112023021037 A2 BR112023021037 A2 BR 112023021037A2 BR 112023021037 A BR112023021037 A BR 112023021037A BR 112023021037 A BR112023021037 A BR 112023021037A BR 112023021037 A2 BR112023021037 A2 BR 112023021037A2
Authority
BR
Brazil
Prior art keywords
right ventricular
gene
ventricular cardiomyopathy
treating
gene therapy
Prior art date
Application number
BR112023021037A
Other languages
English (en)
Portuguese (pt)
Inventor
Farah Sheikh
William Bradford
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112023021037A2 publication Critical patent/BR112023021037A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023021037A 2021-04-12 2022-04-12 Terapia gênica para cardiomiopatia ventricular direita arritmogênica BR112023021037A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163173527P 2021-04-12 2021-04-12
PCT/US2022/024478 WO2022221320A1 (en) 2021-04-12 2022-04-12 Gene therapy for arrhythmogenic right ventricular cardiomyopathy

Publications (1)

Publication Number Publication Date
BR112023021037A2 true BR112023021037A2 (pt) 2023-12-19

Family

ID=83640995

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021037A BR112023021037A2 (pt) 2021-04-12 2022-04-12 Terapia gênica para cardiomiopatia ventricular direita arritmogênica

Country Status (12)

Country Link
US (1) US20240216541A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323534A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514110A (cg-RX-API-DMAC7.html)
KR (1) KR20230170686A (cg-RX-API-DMAC7.html)
CN (1) CN117178057A (cg-RX-API-DMAC7.html)
AU (1) AU2022258329A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021037A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213231A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014900A2 (cg-RX-API-DMAC7.html)
IL (1) IL307506A (cg-RX-API-DMAC7.html)
MX (1) MX2023011875A (cg-RX-API-DMAC7.html)
WO (1) WO2022221320A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
WO2026046394A1 (en) * 2024-09-02 2026-03-05 Inspirar Limited Nucleic acids and uses thereof for plakophilin 2 (pkp2) gene therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7960100B1 (en) * 2004-04-30 2011-06-14 Celera Corporation Colon cancer targets and uses thereof
US20070072175A1 (en) * 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
US8334096B2 (en) * 2009-04-27 2012-12-18 Washington State University Research Foundation Methods and compositions related to arrhythmogenic right ventricular cardiomyopathy (ARVC)
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CN116622704A (zh) * 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
WO2019060619A1 (en) * 2017-09-20 2019-03-28 The Regents Of The University Of California STRATEGY OF GENE THERAPY FOR RESTORING ELECTRICAL AND CARDIAC FUNCTION AND CARDIAC STRUCTURE IN ARYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
EP3820537A4 (en) * 2018-07-12 2022-04-13 Spacecraft Seven, LLC GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
CN114269926A (zh) * 2019-04-26 2022-04-01 美商圣加莫治疗股份有限公司 Aav工程化
TWI897882B (zh) * 2019-09-20 2025-09-21 英商Ucl商業有限責任公司 右心室心律失常性心肌病之基因療法組合物及治療
WO2022032226A1 (en) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector

Also Published As

Publication number Publication date
AU2022258329A9 (en) 2023-10-26
JP2024514110A (ja) 2024-03-28
IL307506A (en) 2023-12-01
WO2022221320A1 (en) 2022-10-20
AU2022258329A1 (en) 2023-10-12
CN117178057A (zh) 2023-12-05
CO2023014900A2 (es) 2023-11-20
MX2023011875A (es) 2024-01-05
EP4323534A1 (en) 2024-02-21
EP4323534A4 (en) 2025-06-18
CA3213231A1 (en) 2022-10-20
KR20230170686A (ko) 2023-12-19
US20240216541A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
BR112022015979A2 (pt) Vetores de terapia genética para tratamento de doenças cardíacas
BR112023001852A2 (pt) Terapia gênica com placofilina-2 (pkp2) usando vetor de aav
Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer?
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
BR112022000836A2 (pt) Composto, composição farmacêutica, método para tratar um mamífero em necessidade do mesmo, processo para produzir um composto, e, intermediário
BR112021021047A2 (pt) Métodos e composições para modulação de emenda e tradução
ZA202303746B (en) Plakophillin-2 gene therapy methods and compositions
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
CO2023014900A2 (es) Tratamiento génico para miocardiopatía arritmogénica del ventrículo derecho
BR112023018944A2 (pt) Composição de terapia gênica e tratamento de cardiomiopatia arritmogênica ventricular direita
BR112021021676A2 (pt) Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal
BR112021025781A2 (pt) Composto, composição farmacêutica, método de tratamento de uma doença ou transtorno associado com um defeito no metabolismo de glioxilato, método de tratamento de uma doença ou transtorno associado com a enzima glicolato oxidase (go) ou alterações no metabolismo de oxalato e método para inibição da enzima go
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112018006445A2 (pt) métodos para tratar distrofia muscular
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
BR112023024741A2 (pt) Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos
BR112021017457A2 (pt) Escetamina para o tratamento de depressão
BR112018076485A8 (pt) Carotenoides microbianos afetando a composição microbiana do intestino
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
BR112018014957A2 (pt) compostos e composições para o tratamento de criptosporidiose
BR112022001002A2 (pt) Solvato de dmf, forma a, forma c, processos para a preparação do solvato de dmf, para a preparação da forma a de relugolix anidra, para a preparação da forma b de relugolix anidra e para a preparação da forma c de relugolix anidra, composição farmacêutica, e, método de tratamento de doença
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
BR112021024534A2 (pt) Métodos para o tratamento da deficiência de alfa-1 antitripsina (aatd)
BR112022015361A2 (pt) Composição farmacêutica para prevenir ou tratar doenças pulmonares, composição de alimentos funcionais para a saúde para melhorar ou prevenir doenças pulmonares e método de prevenção ou tratamento de doenças pulmonares em um indivíduo em necessidade do mesmo
BR112022009607A2 (pt) Inibidores de akt para melhorar a persistência de células t quimericas